SARS-CoV-2 Omicron variant

News and Video Search Results

News coverage

POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

Accesswire 27 Sep 2024

*BUFFALO, NY / ACCESSWIRE / September 27, 2024 / *POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is..

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

GlobeNewswire

23 Sep 2024

Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013m data at ID Week 2024

GlobeNewswire

17 Oct 2024

Ampoules Packaging Market Size Expected to Reach USD 11.27 Bn by 2034
GlobeNewswire 08 Oct 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
GlobeNewswire 20 Sep 2024

0 shares 2 views

You might like

SARS-CoV-2 Omicron variant media coverage

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

GlobeNewswire 12 Sep 2024

· Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout..

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Accesswire 05 Sep 2024
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
GlobeNewswire 04 Sep 2024
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Accesswire 03 Sep 2024
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
GlobeNewswire 03 Sep 2024

Advertisement

More coverage

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

GlobeNewswire 27 Aug 2024

· In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social..

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
ACN Newswire 24 Aug 2024
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
GlobeNewswire 22 Aug 2024
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 05 Aug 2024
Global RT-PCR Test Kits Market Size To Exceed USD 7.12 Billion by 2033 | CAGR Of 5.99%
GlobeNewswire 26 Jul 2024